Venetoclax Results in Durable Efficacy for Relapsed/Refractory CLL

Venetoclax provided long-lasting responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is ...

Patients with relapsed CLL achieving complete remission or undetectable MRD on venetoclax treatment have the most durable responses. Less durable responses are ...

Venetoclax/Rituximab Retreatment Produces Durable Responses in ...

Furthermore, among patients with relapsed/refractory CLL enrolled in the MURANO trial who were retreated with venetoclax plus rituximab (n ...

Venetoclax Monotherapy Shows Deep, Durable Responses in R/R ...

Venetoclax (Venclexta) monotherapy delivered deep and durable responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Venetoclax monotherapy leads to durable responses in R/R chronic ...

Recently published in The Lancet Oncology, the results showed deep and durable responses with venetoclax monotherapy in these patients, ...

Activity of venetoclax in patients with relapsed or refractory chronic ...

Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and ...

An update on the efficacy of Venetoclax for chronic lymphocytic ...

... relapsed/refractory settings. Tumor lysis syndrome (TLS) risk ... venetoclax remains an area of interest with promising results.

Assessment of the Efficacy of Therapies Following Venetoclax ...

Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following ...

Treatment Effectiveness with Venetoclax-Based Therapy after ...

Venetoclax has demonstrated consistent efficacy and manageable toxicity in patients with previously untreated or relapsed/refractory (R/R) ...

Venetoclax: A Real Game Changer in Treatment of Chronic ...

A retrospective study including 23 patients with relapsed/refractory CLL who received a BTKi (ibrutinib, n = 21; zanubrutinib, n = 2) after stopping venetoclax ...

Venetoclax–Rituximab in Relapsed or Refractory Chronic ...

Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of ...

Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

All patients received IVO for 14 cycles of 28 days each. Previous findings showed durable remissions of CLL with the treatment at 4 years. The ...

Deep and Durable Responses Following Venetoclax (ABT-199 ...

2 deaths occurred after PD. Key efficacy data are summarized in the table. Conclusions: VEN plus R induces a high rate of deep and durable responses, ...

Update on the management of relapsed/refractory chronic ... - Nature

The phase III MURANO study demonstrated superior PFS and OS for VenR compared with BR for patients with RR CLL, the majority of whom had one ...

Efficacy of venetoclax monotherapy in patients with relapsed ...

Cheah and colleagues analyzed the effects of immunochemotherapy given after ibrutinib treatment in 31 patients. The ORR was 32% (complete ...

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is ...

Key Points. Patients with relapsed CLL achieving complete remission or undetectable MRD on venetoclax treatment have the most durable responses.Less durabl.

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic ...

In early studies, venetoclax showed unexpected efficacy as monotherapy, with a proportion of patients with high-risk CLL achieving eradication ...

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Although a venetoclax–rituximab regimen involving 24 cycles of venetoclax has led to promising results in patients with relapsed CLL, minimal ...

1908 Treatment Effectiveness with Venetoclax-Based Therapy after ...

Thus, this study demonstrates that venetoclax-based therapy post-cBTKi is associated with durable remission. These results are especially timely ...

durable progression-free survival without long-term treatment 1

VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Important Safety ...